PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Cellular and Molecular Life Sciences0 citationsOpen Access

STAT4 drives optimal expansion and transcriptional repression of type I interferon pathway in inflammatory ILC2

GPGiuseppe PietropaoloGSGianluca ScarnoACArianna Maria Candelotti

Key Points

  • To investigate the role of STAT4 in regulating type I interferon signaling in activated ILC2s during inflammation.
  • Analyzed STAT4 expression in activated type 2 innate lymphocytes (ILC2s) stimulated by IL-25.
  • Examined the effects of STAT4 deficiency on type I interferon signaling and ILC2 proliferation.
  • Conducted transcriptomic analysis of Stat4-deficient ILC2s.
  • Activated ILC2s express elevated levels of STAT4 upon IL-25 stimulation.
  • Despite high STAT4 levels, inflammatory ILC2s do not produce interferon-γ or express T-bet.
  • STAT4 deficiency leads to enhanced type I interferon signaling and impaired ILC2 proliferation.

Abstract

Innate immune cells respond rapidly to environmental cues through signal-regulated transcription factors (SRTFs) that sense changes in the tissue microenvironment. Signal transducer and activator of transcription (STAT) proteins are critical regulators of cytokine signaling and determine polarized immune responses. Herein, we reveal that activated type 2 innate lymphocytes (ILC2s) express STAT4, a SRTF canonically linked to type 1 immunity. STAT4 expression is induced in ILC2s upon activation by the alarmin IL-25 and linked with accumulation of lung inflammatory ILC2s (iILC2s). Despite elevated STAT4 expression, iILC2s do not acquire type 1 features, such as interferon (IFN)-γ production or T-bet expression and do not respond to IL-12 stimulation. Instead, STAT4 is activated by type I IFNs and supports the maintenance of the iILC2 pool. Transcriptomic analysis of Stat4-deficient ILC2s reveals enhanced type I IFN signaling and impaired proliferation, suggesting that STAT4 functions to antagonize IFN-driven suppression. Our data uncover a novel regulatory axis in which IL-25-induced STAT4 expression equips ILC2s to modulate interferon responses and to prevent aberrant autocrine function of type I IFNs, thus sustaining inflammatory effector populations during immune activation. These findings broaden the understanding of ILC2 activation and suggest new avenues for modulating innate lymphocytes in inflammatory diseases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pietropaolo et al. (2026) studied this question.

synapsesocial.com/papers/69c8c115de0f0f753b39ba7dhttps://doi.org/10.1007/s00018-026-06157-6
Ask AI
Helpful
Bookmark
Share
View Full Paper